Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioMarket CapitalizationNet MarginOperating MarginReturn on SalesTimes Interest Earned

Solid Biosciences (SLDB) Equity Average: 2018-2024

Historic Equity Average for Solid Biosciences (SLDB) over the last 7 years, with Sep 2024 value amounting to $180.1 million.

  • Solid Biosciences' Equity Average rose 16.94% to $180.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $180.1 million, marking a year-over-year increase of 16.94%. This contributed to the annual value of $169.1 million for FY2023, which is 19.47% down from last year.
  • Per Solid Biosciences' latest filing, its Equity Average stood at $180.1 million for Q3 2024, which was down 10.82% from $202.0 million recorded in Q2 2024.
  • In the past 5 years, Solid Biosciences' Equity Average ranged from a high of $245.5 million in Q2 2021 and a low of $31.5 million during Q3 2020.
  • For the 3-year period, Solid Biosciences' Equity Average averaged around $173.9 million, with its median value being $173.9 million (2022).
  • In the last 5 years, Solid Biosciences' Equity Average slumped by 65.98% in 2020 and then skyrocketed by 632.88% in 2021.
  • Solid Biosciences' Equity Average (Quarterly) stood at $77.2 million in 2020, then surged by 179.67% to $215.8 million in 2021, then dropped by 17.76% to $177.5 million in 2022, then dropped by 23.69% to $135.4 million in 2023, then rose by 16.94% to $180.1 million in 2024.
  • Its Equity Average stands at $180.1 million for Q3 2024, versus $202.0 million for Q2 2024 and $168.6 million for Q1 2024.